Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Kunitada

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
European Journal of Pharmacology|February 14, 1991
A thromboxane A2 synthase inhibitor, DP-1904, prevents rat renal injuryH Masumura, S Kunitada, K Irie, et al.
Thrombosis and Haemostasis|May 6, 2011
Effect of edoxaban on markers of coagulation in venous and shed blood compared with fondaparinuxM Wolzt, M M Samama, S Kapiotis, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 1, 1991
A prostacyclin analog impairs the response to tissue-type plasminogen activator during coronary thrombolysis: evidence for a pharmacokinetic interactionD M Kerins, M Shuh, S Kunitada, et al.
Chemical & Pharmaceutical Bulletin|May 1, 1996
Amino acids and peptides. XXVII. Solid phase synthesis of fibrinogen-related peptides with disulfide bond formed on solid supportM Kakiuchi, Y Izuno, M Maeda, et al.
Advances in Cyclic Nucleotide Research|January 1, 1980
Adrenergic and cholinergic modulation of extracellular cyclic nucleotidesM Ui, M Honma, S Kunitada, et al.
Circulation|February 1, 1992
Pharmacokinetics of tissue-type plasminogen activator during acute myocardial infarction in men. Effect of a prostacyclin analogueD M Kerins, L Roy, S Kunitada, et al.
Clinical Pharmacology and Therapeutics|October 8, 1999
Tolerability, pharmacokinetics, and pharmacodynamics of DX-9065a, a new synthetic potent anticoagulant and specific factor Xa inhibitor, in healthy male volunteersN Murayama, M Tanaka, S Kunitada, et al.
Circulation|August 1, 1995
Antithrombotic effects of orally active synthetic antagonist of activated factor X in nonhuman primatesT Yokoyama, A B Kelly, U M Marzec, et al.
Thrombosis and Haemostasis|June 12, 1999
DX-9065a, an orally active factor Xa inhibitor, does not facilitate haemorrhage induced by tail transection or gastric ulcer at the effective doses in rat thrombosis modelK Tanabe, Y Morishima, T Shibutani, et al.
Journal of Thrombosis and Haemostasis : JTH|March 6, 2004
Initial experience with factor-Xa inhibition in percutaneous coronary intervention: the XaNADU-PCI PilotJ H Alexander, C K Dyke, H Yang, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
European Journal of Pharmacology|February 14, 1991
A thromboxane A2 synthase inhibitor, DP-1904, prevents rat renal injuryH Masumura, S Kunitada, K Irie, et al.
Thrombosis and Haemostasis|May 6, 2011
Effect of edoxaban on markers of coagulation in venous and shed blood compared with fondaparinuxM Wolzt, M M Samama, S Kapiotis, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 1, 1991
A prostacyclin analog impairs the response to tissue-type plasminogen activator during coronary thrombolysis: evidence for a pharmacokinetic interactionD M Kerins, M Shuh, S Kunitada, et al.
Chemical & Pharmaceutical Bulletin|May 1, 1996
Amino acids and peptides. XXVII. Solid phase synthesis of fibrinogen-related peptides with disulfide bond formed on solid supportM Kakiuchi, Y Izuno, M Maeda, et al.
Advances in Cyclic Nucleotide Research|January 1, 1980
Adrenergic and cholinergic modulation of extracellular cyclic nucleotidesM Ui, M Honma, S Kunitada, et al.
Circulation|February 1, 1992
Pharmacokinetics of tissue-type plasminogen activator during acute myocardial infarction in men. Effect of a prostacyclin analogueD M Kerins, L Roy, S Kunitada, et al.
Clinical Pharmacology and Therapeutics|October 8, 1999
Tolerability, pharmacokinetics, and pharmacodynamics of DX-9065a, a new synthetic potent anticoagulant and specific factor Xa inhibitor, in healthy male volunteersN Murayama, M Tanaka, S Kunitada, et al.
Circulation|August 1, 1995
Antithrombotic effects of orally active synthetic antagonist of activated factor X in nonhuman primatesT Yokoyama, A B Kelly, U M Marzec, et al.
Thrombosis and Haemostasis|June 12, 1999
DX-9065a, an orally active factor Xa inhibitor, does not facilitate haemorrhage induced by tail transection or gastric ulcer at the effective doses in rat thrombosis modelK Tanabe, Y Morishima, T Shibutani, et al.
Journal of Thrombosis and Haemostasis : JTH|March 6, 2004
Initial experience with factor-Xa inhibition in percutaneous coronary intervention: the XaNADU-PCI PilotJ H Alexander, C K Dyke, H Yang, et al.
Pageof 2